Regadenoson

Top

Home > Library > Miscellaneous > Wikipedia

Regadenoson

Systematic (IUPAC) name
2-{4-[(methylamino)carbonyl]- 1H-pyrazol-1-yl}adenosine
Clinical data
AHFS/Drugs.com	Multum Consumer Information
Licence data	US FDA:link
Pregnancy cat.	C(US)
Legal status	℞-only (US)
Routes	Intravenous
Identifiers
CAS number	313348-27-5^Y 875148-45-1
ATC code	C01EB21
PubChem	CID 219024
UNII	7AXV542LZ4^N
KEGG	D05711^Y
ChEMBL	CHEMBL1201750^N
Synonyms	1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]- N-methylpyrazole-4-carboxamide
Chemical data
Formula	C₁₅H₁₈N₈O₅
Mol. mass	390.354 g/mol
N(what is this?) (verify)

Regadenoson (INN, code named CVT-3146) is an A_2A adenosine receptor agonist that is a coronary vasodilator. It produces maximal hyperemia quickly and maintains it for an optimal duration that is practical for radionuclide myocardial perfusion imaging.^[1]

It was approved by the United States Food and Drug Administration on April 10, 2008 and is marketed by Astellas Pharma under the tradename Lexiscan.^[2] It has now gained approval in the European Union and is being sold under the name of Rapiscan. It is currently being Marketed by GE Healthcare and is being sold in both the United Kingdom and Germany.

Regadenoson has a 2- to 3-minute biological half-life, as compared with adenosine's 30-second half-life. Regadenoson stress protocols using a single bolus have been developed, obviating the need for an intravenous line. Regadenoson stress tests are not affected by the presence of beta blockers, as regadenoson vasodilates but does not stimulate beta adrenergic receptors.^{[citation needed]}

References

^ Cerqueira MD (July 2004). "The future of pharmacologic stress: selective A2A adenosine receptor agonists". Am. J. Cardiol. 94 (2A): 33D–40D; discussion 40D–42D. doi:10.1016/j.amjcard.2004.04.017. PMID 15261132. http://linkinghub.elsevier.com/retrieve/pii/S0002914904005934.
^ CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM)

Adenosinergics

Receptor ligands

Agonists	2-(1-Hexynyl)-N-methyladenosine • 2-Cl-IB-MECA • 2'-MeCCPA • 5'-N-ethylcarboxamidoadenosine • ATL-146e • BAY 60–6583 • CCPA • CGS-21680 • CP-532,903 • GR 79236 • LUF-5835 • LUF-5845 • N6-Cyclopentyladenosine • Regadenoson • SDZ WAG 994 • UK-432,097

Antagonists	8-Phenyl-1,3-dipropylxanthine • Acefylline • Aminophylline • Bamifylline • Caffeine • CGS-15943 • 8-Chlorotheophylline • CPX • CVT-6883 • Dimethazan • DPCPX • Fenethylline • Istradefylline • KF-26777 • MRE3008F20 • MRS-1220 • MRS-1334 • MRS-1706 • MRS-1754 • MRS-3777 • Paraxanthine • Pentoxifylline • Preladenant • Propentofylline • PSB-10 • PSB-11 • PSB 36 • PSB-603 • PSB-788 • PSB-1115 • Rolofylline • SCH-442,416 • SCH-58261 • Theobromine • Theophylline • VUF-5574 • ZM-241,385

Reuptake inhibitors

Plasmalemmal

ENT inhibitors	Dilazep • Dipyridamole • Hexobendine • Pentoxifylline • Propentofylline

Vesicular

VNT inhibitors

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)

Donate to Wikimedia

Post a question - any question - to the WikiAnswers community:

Copyrights:

Cite

Wikipedia on Answers.com This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article Regadenoson. Read